Actual - Finance

People who are in serious debt in the U.K. have the option of proposing an IVA, or Individual Voluntary Arrangement to their creditors as a means of clea

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

ring their debt whilst avoiding Bankruptcy.

An IVA will generally lasts for 5 years, over which time, monthly repayments are made to the creditors throu

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

gh an insolvency practitioner, but when the correct circumstances are in place, it is possible to propose an IVA that consists of just one payment.

This

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

IVA is referred to as a 'Full and Final Settlement' or 'Lump Sum IVA'.

The circumstances that tend to favour the 'Lump Sum' IVA as an option are quite

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

pecific and not all potential IVA cases will be suitable.

Firstly, the debtor must qualify for an IVA under the normal criteria of having over ?15,000 i

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

n unsecured debts which are owed to a minimum of 4 creditors.

Secondly, the debtor must have very little, if any, disposable income with which to make t

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

heir monthly contributions.

Thirdly, the debtor will need to have access to enough releasable equity from a property they own, or know a third party tha

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

t is prepared to introduce a sufficiently high lump sum and act as their benefactor.

Fourthly, the lump sum should be at least 25% of the total d

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

bts, plus enough excess left over to cover the costs to the creditors.

When these conditions arise, a 'Full and Final Settlement' IVA or 'Lump Sum IVA'

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

becomes a distinct possibility.

The initial stages of the IVA are the same as ever. An Insolvency Practitioner is chosen to act on behalf of the debtor

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

and they gather all the relevant paperwork and details required for the proposal to the creditors. It is likely the Insolvency Practitioner will request

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

the settlement funds be transferred to their client account whilst preparations for the IVA are being made, and they would hold the funds there ready for

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

the transfer to the creditors as soon as the IVA has been agreed.

Once the IVA has been agreed by the creditors in the normal manner, all the benefits o

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

f a standard IVA apply, but instead of making monthly contributions for 5 years, the lump sum is transferred to the creditors, and the IVA concludes on r

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

eceipt of the one payment. As with all successfully completed IVAs, the balance of any debt that hasn't been repaid is written off by the creditors, leav

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

ing the debtor debt free. Because the IVA is a binding agreement, the creditors are unable to accept the funds and then change their minds and ask for fu

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

ther repayments. The debt is legally settled.

There are advantages for the creditors too of course. They receive a repayment from a debtor who would hav

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

e struggled to repay the debt, as there is little if any surplus income. They receive a lump sum immediately rather than having to wait for a long winded

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

return, and also because the IVA finishes so quickly, the fees the creditors have to pay to the Insolvency Practitioner are reduced, leaving them with a

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

higher return from the debt.

A Lump Sum IVA will not always be a suitable solution, but when the circumstances are fitting, it really is a great option

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.actual.org.ua/article/100307/actual-The-Lump-Sum-IVA-A-Full-And-Final-Settlement.html">The Lump Sum IVA: A Full And Final Settlement</a>

BB link (for phorums):
[url=http://www.actual.org.ua/article/100307/actual-The-Lump-Sum-IVA-A-Full-And-Final-Settlement.html]The Lump Sum IVA: A Full And Final Settlement[/url]

As marketers and businesses seek to promote themselves, their products or events, they need to think through the promotional products they use in the promotion. They need to consider the positives and explore possible negatives. A product that may seem like a sure-fire hit may actually turn into a public relations problem. A prime example of this is Temporary Tattoos.

If you want a number 1 ranked site for your keywords, you need to know about SEO.

People who intend to reduce their financial burdens by consolidating their multiple loans into one, find online debt consolidation services very useful. A mere click of the mouse opens various options for an individual to amalgamate different loans into a single loan. Instead of making various payments, debt consolidation ensures a single monthly payment against all outstanding debt.

Tags

Links

Actual - The Lump Sum IVA: A Full And Final Settlement

Related Articles: